Form 8-K

8-K — Jasper Therapeutics, Inc.

Accession: 0001213900-26-109587

Filed: 2026-10-15

Period: 2026-10-15

CIK: 0001788028

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0308657-8k_jasper.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED OCTOBER 15, 2026 (ea030865701ex99-1.htm)

GRAPHIC (ea030865701_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0308657-8k_jasper.htm · Sequence: 1

false

0001788028

2026-10-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 15, 2026

JASPER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39138

84-2984849

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

2200 Bridge Pkwy Suite #102

Redwood City, CA

94065

(Address of principal executive offices)

(Zip Code)

(650) 549-1400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Voting Common Stock, par value $0.0001 per share

JSPR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 15, 2026, Jasper

Therapeutics, Inc. issued a press release announcing that it completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2

basket study evaluating vensobafusp alfa (KP104).

A copy of the press release

is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated October 15, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JASPER THERAPEUTICS, INC.

Date: October 15, 2026

By:

/s/ Jeet Mahal

Name:

Jeet Mahal

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED OCTOBER 15, 2026

EX-99.1

Filename: ea030865701ex99-1.htm · Sequence: 2

Exhibit 99.1

Jasper Therapeutics Announces Completion of

Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Initial

Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026

Announces

expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027

REDWOOD CITY, Calif., October 15, 2026 (GLOBE

NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology

company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed

enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a first-in-class bifunctional

biologic that simultaneously and selectively targets both the alternative and terminal complement pathways.

The Company expects to report initial interim

data from the IgAN basket study by year-end 2026. In addition, Jasper has accelerated the initiation of an additional cohort to the study

evaluating vensobafusp alfa in focal segmental glomerulosclerosis (FSGS), with the first patient anticipated to be dosed in the first

quarter 2027.

“Completing enrollment of the first IgAN

cohort on schedule reflects both the high unmet need in this disease and strong execution by our clinical teams at Jasper and Kira,”

said Greg Keenan, M.D., Chief Medical Officer of Jasper. “We are now expanding the study to include a cohort of patients with FSGS,

a rare and severe kidney disease that often progresses to kidney failure. We believe vensobafusp alfa’s bifunctional ability to

inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement

driven diseases. We look forward to reporting initial data from the IgAN cohort by the end of this year and are actively working towards

dosing the first patients with FSGS in first quarter 2027.”

A total of 18 patients with IgAN were enrolled

in stage 1 of the Phase 2 basket study across 3 cohorts evaluating an induction regimen followed by subcutaneous Q2W (n=6), Q4W (n=6),

or Q8W (n=6) maintenance dosing. The objective of stage 1 is to assess the safety, tolerability and initial efficacy in IgAN, and help

determine optimal dose levels for further evaluation.

The Phase 2 basket study is evaluating the efficacy,

safety, tolerability, pharmacokinetics, and pharmacodynamics of vensobafusp alfa in China to provide proof-of-concept in several renal

diseases, including IgAN, complement 3 glomerulopathy (C3G) and FSGS. The Company is exploring the addition of further cohorts evaluating

vensobafusp alfa in other complement-mediated kidney diseases.

About IgA Nephropathy

IgA Nephropathy (IgAN) is an autoimmune disease

that damages the kidneys, impacting organ function and often resulting in end-stage kidney disease. IgAN is the most common form of glomerulonephritis,

with a global population incidence of roughly 2.5 per 100,000 per year, though the exact pathogenesis of the disease remains unknown.

In IgAN, the body produces abnormal immunoglobulin A (IgA) antibodies that stimulate an immune response and result in formation of immune

complexes that become trapped in the kidney. The immune complexes in the kidney cause inflammation and tissue damage, potentially leading

to renal failure. Despite current advancements, there remains substantial unmet need in the treatment of IgA Nephropathy. Recent studies

have implicated aberrant complement activity as a major contributor to glomerular inflammation and disease progression of IgAN. Vensobafusp

alfa is designed to inhibit the alternative and terminal complement pathways and is being evaluated for its potential to address IgAN

through selective modulation of complement activity.

About Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a

rare kidney disorder characterized by progressive scarring of the kidney and excess protein in the urine, leading to various symptoms

including high blood pressure, proteinuria, edemas, fatigue, weight gain, and cholesterol increase. FSGS is a leading glomerular cause

of end-stage kidney disease in the U.S. and only a single FDA-approved therapy is available. The current standard of care consists of

steroids and/or other immunosuppressives and antihypertensives which lead to modest slowing of progression to kidney failure. The Company

believes there remains a substantial unmet need in FSGS and that vensobafusp alfa has the potential to improve clinical outcomes for patients.

About Vensobafusp Alfa (KP104)

Vensobafusp alfa (KP104) is a first-in-class bifunctional

biologic designed to simultaneously block both the alternative and terminal complement pathways, which Jasper believes may provide a differentiated

approach to targeting drivers of complement-mediated disease. This dual-target mechanism of action is intended to address complement-mediated

diseases and may potentially provide greater benefits than single-target complement agents, although no comparative or head-to-head studies

have been conducted. Engineered to have an extended half-life and enhanced potency, vensobafusp alfa has a formulation suitable for both

intravenous and subcutaneous administrations. Vensobafusp alfa is being evaluated in Phase 2 POC trials across multiple renal diseases

and hematologic indications and has been granted Orphan Drug Designation by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria

(PNH). Previously presented 2-year clinical data from a separate open-label Phase 2 study in a limited number of patients with PNH showed

normalization of hemoglobin and reductions in LDH. Jasper plans to conduct Phase 2/3 trials globally, including in the U.S. and China,

as well as in other jurisdictions, subject to regulatory feedback. Vensobafusp alfa is an investigational agent not yet approved for any

indication by any health authority.

About Jasper

Jasper is a clinical stage biotechnology company

focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of

medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor

that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need

nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent

for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as

the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently

advancing to the clinic.

Forward-Looking Statements

Certain statements contained in this press release

are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995.

These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,”

“expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,”

“projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial

performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s

management and are subject to significant risks, uncertainties and assumptions, including, without limitation, the uncertainties associated

with the Company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product

candidates, including potential delays in the commencement, enrollment and completion of clinical trials; ; risks that initial, interim

or topline results from early-stage or open-label studies, including results in a limited number of patients, may not be predictive of,

and may differ materially from, results from later stages of the same study or from later-stage or larger trials; risks related to the

inability of the Company to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs;

uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related

to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in

light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible

failure to realize certain anticipated benefits of the merger, including with respect to future financial and operating results; and such

additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for

the year ended December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or

may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation,

those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory

review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and product candidates and

regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans,

future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations,

statements regarding the Company and its operations and prospects, may not occur, and actual results could differ materially and adversely

from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking

events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially

and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking

statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any

reason after the date of this press release or to conform these statements to actual results or to changes in the Company’s expectations,

whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as

may be required under applicable securities laws.

Contacts:

Alex Gray (investors)

Jasper Therapeutics

650-549-1454

agray@jaspertx.com

Argot Partners (investors and media)

kira@argotpartners.com

GRAPHIC

Filename: ea030865701_ex99-1img1.jpg · Sequence: 3

Binary file (22907 bytes)

Download ea030865701_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 15, 2026

Entity File Number

001-39138

Entity Registrant Name

JASPER THERAPEUTICS, INC.

Entity Central Index Key

0001788028

Entity Tax Identification Number

84-2984849

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2200 Bridge Pkwy Suite #102

Entity Address, City or Town

Redwood City

Entity Address, State or Province

Entity Address, Postal Zip Code

94065

City Area Code

650

Local Phone Number

549-1400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Voting Common Stock, par value $0.0001 per share

Trading Symbol

JSPR

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration